ClinicalTrials.gg

Program

tofacitinib

Also written as “CP-690,550”, “Tofacitinib” and “tofacitinib modified-release (MR) formulation”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 4 companies.

Furthest: phase 4, since Mar 3, 201491 company-led studies, 1 open or runningNext primary completion: Mar 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer881 open or runningphase 4since Mar 3, 2014Mar 28, 2005Mar 17, 2027phase 3 · NCT04624230
CAGE Bio10 open or runningphase 2since Aug 1, 2022Aug 1, 2022none ahead
Johnson & Johnson10 open or runningphase 1since Jul 22, 2021Jul 22, 2021none ahead
TWi Biotechnology10 open or runningphase 1since Jul 7, 2020Jul 7, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jun 9, 2010.

  1. Aug 14, 2015Phase 3 study in Arthritis, JuvenilePfizer · NCT02592434 · 225 enrolled · United States, Argentina, Australia and more
  2. Jul 11, 2016Phase 4 study in Arthritis, RheumatoidPfizer · NCT02831855 · 694 enrolled · United States, Australia, Belgium and more
  3. Nov 9, 2016Phase 3 study in Arthritis, JuvenilePfizer · NCT03000439 · 100 enrolled · United States, Argentina, Belgium and more
  4. Sep 11, 2017Phase 4 study in Colitis, UlcerativePfizer · NCT03281304 · 140 enrolled · United States, Belgium, Canada and more
  5. Mar 5, 2018Phase 3 study in Arthritis, PsoriaticPfizer · NCT03486457 · 204 enrolled · China
  6. Apr 11, 2018Phase 3 study in Spondylitis, AnkylosingPfizer · NCT03502616 · 270 enrolled · United States, Australia, Bulgaria and more
  7. Sep 30, 2019Phase 1 study in HealthyPfizer · NCT04111614 · 12 enrolled · United States
  8. Mar 11, 2020Phase 1 study in HealthyPfizer · NCT04338711 · 23 enrolled · United States
  9. May 4, 2020Phase 1 study in HealthyPfizer · NCT04403776 · 26 enrolled · China
  10. May 19, 20202 phase 2 studiesPfizer · NCT04413617, NCT04412252
  11. Jul 7, 2020TWi Biotechnology's first study: phase 1 study in Healthy SubjectsNew to TWi BiotechnologyTWi Biotechnology · NCT04468425 · 20 enrolled · Canada
  12. Oct 26, 2020Phase 3 study in Colitis, UlcerativePfizer · NCT04624230 · 118 enrolled · United States, Australia, Belgium and more
  13. Jul 22, 2021Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT04985955 · 12 enrolled · Belgium
  14. Aug 1, 2022CAGE Bio's first study: phase 2 study in Dermatitis, AtopicNew to CAGE BioCAGE Bio · NCT05487963 · 40 enrolled · Georgia

Ahead

  1. Mar 17, 2027Primary completion: phase 3 study in Colitis, UlcerativePfizer · NCT04624230

TargetBeta

“Janus Kinase (JAK) inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

The newest 60 of 91 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT05487963Dermatitis, Atopic · Georgia2CompletedCAGE BioJun 30, 202340
NCT04985955Healthy · Belgium1CompletedJohnson & JohnsonSep 21, 202112
NCT04624230Colitis, Ulcerative · United States, Australia, Belgium and more3Active, not recruitingPfizerMar 17, 2027118
NCT04468425Healthy Subjects · Canada1CompletedTWi BiotechnologyDec 21, 202020
NCT04412252COVID-19 · United States2WithdrawnPfizerSep 16, 20200
NCT04413617Arthritis, Rheumatoid · Bulgaria, Canada, Chile and more2CompletedPfizerFeb 7, 2022460
NCT04403776Healthy · China1CompletedPfizerFeb 12, 201926
NCT04338711Healthy · United States1CompletedPfizerSep 15, 202023
NCT04111614Healthy · United States1CompletedPfizerDec 12, 201912
NCT03502616Spondylitis, Ankylosing · United States, Australia, Bulgaria and more3CompletedPfizerDec 19, 2019270
NCT03486457Arthritis, Psoriatic · China3CompletedPfizerApr 28, 2021204
NCT03281304Colitis, Ulcerative · United States, Belgium, Canada and more4TerminatedPfizerFeb 14, 2020140
NCT03000439Arthritis, Juvenile · United States, Argentina, Belgium and more3CompletedPfizerMar 27, 2024100
NCT02831855Arthritis, Rheumatoid · United States, Australia, Belgium and more4CompletedPfizerNov 19, 2018694
NCT02592434Arthritis, Juvenile · United States, Argentina, Australia and more3CompletedPfizerMay 16, 2019225
NCT02281552Arthritis, Rheumatoid · Japan3CompletedPfizerMar 15, 2017209
NCT02187055Rhematoid Arthritis · United States, Argentina, Australia and more4CompletedPfizerDec 20161,152
NCT02147587Arthritis, Rheumatoid · United States2CompletedPfizerJun 2015112
NCT02084875Healthy · United States1CompletedPfizerMay 25, 201424
NCT02092467Arthritis, Rheumatoid · United States, Argentina, Australia and more4CompletedPfizerJul 22, 20204,372
NCT02001181Dermatitis, Atopic · Canada2CompletedPfizerSep 201469
NCT01976364Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedPfizerMay 20, 2019686
NCT01882439Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedPfizerApr 2016395
NCT01877668Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedPfizerDec 18, 2015422
NCT01831466Psoriasis · United States, Canada, Denmark and more2CompletedPfizerSep 2014476
NCT01815424Psoriasis · China, Korea, Republic of, Taiwan3CompletedPfizerJul 2015266
NCT01786668Spondylitis, Ankylosing · United States, Canada, Czech Republic and more2CompletedPfizerMar 2015208
NCT01745055Arthritis, Rheumatoid · United States1CompletedPfizerJun 200612
NCT01736696Psoriasis · United States1CompletedPfizerApr 200459
NCT01731327Healthy · Singapore1CompletedPfizerDec 201220
NCT01743677Healthy · Belgium, Singapore1CompletedPfizerFeb 7, 200860
NCT01740362Renal Insufficiency · United States1CompletedPfizerMar 200424
NCT01710046Plaque Psoriasis · United States2CompletedPfizerNov 201312
NCT01710033Kidney Transplant · United States1CompletedPfizerApr 200528
NCT01710020Kidney Failure, Chronic · United States1CompletedPfizerJun 200312
NCT01599377Healthy · Singapore1CompletedPfizerJul 201250
NCT01513902Arthritis, Juvenile · United States, Germany, Poland and more1CompletedPfizerDec 201526
NCT01519089Psoriasis · Japan3CompletedPfizerJan 201495
NCT01500551Arthritis, Juvenile · United States, Argentina, Australia and more3CompletedPfizerFeb 12, 2025302
NCT01499004Healthy · Singapore1CompletedPfizerDec 201130
NCT01470599Crohn Disease · United States, Australia, Austria and more2CompletedPfizerJul 2016150
NCT01470612Colitis, Ulcerative · United States, Australia, Austria and more3CompletedPfizerAug 6, 2020944
NCT01465763Colitis, Ulcerative · United States, Australia, Austria and more3CompletedPfizerMay 2015614
NCT01458951Colitis, Ulcerative · United States, Australia, Austria and more3CompletedPfizerMay 2015547
NCT01458574Colitis, Ulcerative · United States, Australia, Austria and more3CompletedPfizerMay 27, 2016593
NCT01393899Crohn Disease · United States, Australia, Austria and more2CompletedPfizerJul 2015180
NCT01393626Crohn Disease · United States, Australia, Austria and more2CompletedPfizerFeb 2015280
NCT01359150Arthritis, Rheumatoid · United States, Poland2CompletedPfizerFeb 2012223
NCT01309737Psoriasis · United States, Canada, Colombia and more3CompletedPfizerApr 2013960
NCT01276639Psoriasis · United States, Canada, Colombia and more3CompletedPfizerApr 2013901
NCT01246583Psoriasis · United States, Canada2CompletedPfizerNov 29, 201171
NCT01262118Arthritis, Rheumatoid · United States, Hungary1CompletedPfizerJan 201269
NCT01241591Psoriasis · Argentina, Austria, Belgium and more3CompletedPfizerJan 20131,101
NCT01226680Keratoconjunctivitis Sicca2WithdrawnPfizerOct 19, 20120
NCT01204112Healthy · United States1CompletedPfizerOct 201012
NCT01186744Psoriasis · United States, Argentina, Australia and more3CompletedPfizerJan 2013666
NCT01185184Healthy · Singapore1CompletedPfizerAug 201012
NCT01164579Arthritis, Rheumatoid · United States, Argentina, Chile and more2CompletedPfizerNov 2013109
NCT01163253Psoriasis · United States, Argentina, Australia and more3TerminatedPfizerJun 20162,867
NCT01143805Arthritis, Rheumatoid · Singapore1CompletedPfizerAug 201012

How it is read

Names in the registry

  • “CP-690,550”, 102 entries
  • “Tofacitinib”, 19 entries
  • “tofacitinib”, 11 entries
  • “tofacitinib modified-release (MR) formulation”, 4 entries
  • “CP- 690 550”, 4 entries

Codes read as this program: CP690.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.